


Set up your account



My profile - Your profile details are displayed in 'Find a Specialist'

Personal info
Tell us a bit about yourself!

First name: *
Sigrid

Last name: *
Blaser

Title: *
Ms

Company Name: *
MyopiaCare by Eyetific Headquarter

Address: *
Rue du Lac 32b

Address 2:
Address 2

Zip Code: *
1020

City: *
Brussels

Select Country: *
Switzerland

Email address: *
info@eyetific.com

Phone #: *
+41 797817337

Mobile #: *
+99-99-9999-9999

Facebook URL:
https://www.facebook.com/myopia.care

Twitter URL:
https://twitter.com/myopicare

LinkedIn URL:
http://

Website URL:
https://eyetific.com/

Fax:
Fax

Preferred Method of Contact: *
Email

Visual acuity scales: *
LogMAR

Date Format: *
DD/MM/YYYY

Change profile photo
No file selected
Allow only .jpg, .gif, .png file types to be uploaded. Maximum file size 5MB.

Upload your company logo

Public Pro

Public Test

Find a specialist

Share this App

Eyetific by Sigrid Blaser
Rue du Lac 32b
1020 Brussels
+41797817337, info@eyetific.com
9:00 - 17:00 weekdays
Directions Zoom here Street view

Share patient report - Customize the 'Share' page

Add personalized information to the 'Share' page

Your custom text
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sancta est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sancta est Lorem ipsum dolor sit amet.

Worldwide Myopia Prevalence

Year	Prevalence (%)
2010	28%
2020	40%
2030	50%

Share patient report

QR code

Your custom text
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sancta est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sancta est Lorem ipsum dolor sit amet.

Worldwide Myopia Prevalence

Year	Prevalence (%)
2010	28%
2020	40%
2030	50%

Products - Select and adjust the 'Product list' for treatment

Products List

Which product group will be displayed / Ability to Deselect Control Rate percentage

Product Group	Control Rate %	Enabled?
Soft multifocal contact lenses	44	Yes
Orthokeratology	45	Yes
Orthokeratology multifocal	45	Yes
ASP multifocal	5	Yes
Atropine 0.01%	21	Yes
Defocus Segment Spectacle lens	95	Yes
Anti-Myopia soft contacts	39	Yes
Executive Bifocals	31	Yes
Progressive Addition Spectacle lens	24	Yes
Anti-Myopia Orthokeratology	50	Yes
Atropine 0.025%	41	Yes
Atropine 0.05%	47	Yes
No treatment	0	Yes
Peripheral Progressive spectacle lens	38	Yes

Open Changes

Date: Select a date


Treatment (select max 4 options)

Product Multifocal CD
Soft Multifocal CD
ASP Multifocal CD
Mimion 2 Stage Tonic
Mimion Individual
FLX-VM


ADD New Patient

 New Patient ▾

+ Add patient w/o public code

 Add patient using public code

Add patient using public code



Add patient using public code

Enter Code

IMPORT

Patient Info

Patient ID from PRO: *	Gender: *	Date Of Birth: *
<input type="text" value="Patient ID from PRO"/>	<input type="text" value="Gender"/>	<input type="text" value="Select a date"/>
Select Country:	Ethnic group: *	Risk Factor
<input type="text" value="Select Country"/>	<input type="text" value="Ethnic group"/>	<input type="text" value="Default Literatur review progression rate"/>

Submit

Risk Profile
Automatic selected from
'public questionnaire'
result

Add patient without public code

+ Add patient w/o public code

Patient Info

Patient ID from PRO: *	Gender: *	Date Of Birth: *
<input type="text" value="Patient ID from PRO"/>	<input type="text" value="Gender"/>	<input type="text" value="Select a date"/>
Select Country:	Ethnic group: *	Risk Factor
<input type="text" value="Select Country"/>	<input type="text" value="Ethnic group"/>	<input type="text" value="Default Literatur review progression rate"/>

Submit

Risk Profile
Select from our own
risk analysis


My Records

Filter Patient Code

Show: 10

Filter:

Patient Code	Date Of Birth	Gender	Ethnicity	Risk profile	Actions
ABC	03/09/2019	Male	Asian	ADD	
EB 2007	05/04/2007	Female	White	Yes	
New DOB	12/12/2017	Male	Asian	Yes	



Patient data



Edit Patient Add ddata

Patient data

EB 2007	05/04/2007	Female	Default Literatur review progression rate
---------	------------	--------	---

Show: 10

Filter:

Date	SPH Right	SPH Left	Right Eye Lenght	Left Eye Length	Cyclo	Treatment	Used in Annual Growth chart?	Actions
2024-06-09	-2.25	-2.5	25.03	25.04	Y	MIYOSMART	Yes	
2023-10-09	-2	-2.25	24.98	24.99	Y	MIYOSMART	Yes	
2023-03-07	-2	-2	24.90	24.90	Y	MIYOSMART	Yes	
2022-08-09	-2	-2.25	24.92	24.94	Y	Relax SL3, MIYOSMART	Yes	
2021-10-21	-1.75	-2	24.85	24.88	Y	Relax SL3, MIYOSMART	Yes	
2020-09-09	-1.75	-1.75	24.77	24.79	Y	MIYOSMART	Yes	
2019-09-03	-1.75	-1.75	24.69	24.70	Y	MIYOSMART	Yes	

Add ddata

Actions



Edit patient data

Delete data point

Patient data

Patient data overview

📄 📊 🔍 🔍 🖨️ 📄 📄

Edit Patient + Add data

Patient data

EB 2007 05/04/2007 Female Default Literatur review progression rate

Show: 10 Filter:

Date	SPH Right	SPH Left	Right Eye Lenght	Left Eye Length	Cyclo	Treatment	Used In Annual Growth chart?	Actions
2024-06-09	-2.25	-2.5	25.03	25.04	Y	MIYOSMART	Yes	✎ 🗑️
2023-10-09	-2	-2.25	24.98	24.99	Y	MIYOSMART	Yes	✎ 🗑️
2023-03-07	-2	-2	24.90	24.90	Y	MIYOSMART	Yes	✎ 🗑️

ADD or EDIT Patient data

Add new data for this patient

EB 2007 05/04/2007 Female Default Literatur review progression rate

Date: Select date of measurement

Treatment: (select max 4 options)

Select up to 4 treatments

Measured under cycloplegia

Length of the eye in mm

OO: Select if measurement should be used in the annual eye growth graph

OS: Use record for annual growth calculation

🔍

Annual Eye Growth


🔍

Eye Growth Curve

📊

MyAppia

Prediction of myopia progression till age 17



Predicted prescription with age of 17 if untreated from start: **-3.77D**

Select to display or hide the treatment

Predicted prescription with age of 17 if untreated from start: **-3.77D**


Calculation of myopia progression from the first data point until age 17, based on study data (Sankaridurg et al. 2014¹) and risk profile.

Data points for the patient, treatments, and the untreated eye. Appears when mouse hovers over

1. Sankaridurg PR, Holden BA. Practical applications to modify and control the development of ametropia. Eye (Lond). 2014 Feb;28(2):134-41. doi: 10.1038/eye.2013.255. Epub 2013 Dec 6. PMID: 24310242; PMCID: PMC3930267.

Eye Growth Curve

Eye length as an age-related risk factor for myopia



Additional information for the consultation

- » Current eye length vs. average emmetropic eye length¹
- » Estimated eye length if untreated²
- » Current eye length of the patient


Data points for the patient and virtual percentage treatment efficacy³ compared to the calculated untreated eye growth²

Appears when mouse hovers over

1. Tideman JW et al., Axial length growth and the risk of developing myopia in European children. *Acta Ophthalmol.* 2018 May;96(3):301-309. doi: 10.1111/aos.13603. Epub 2017 Dec 19. PMID: 29265742; PMCID: PMC6002955.
2. Brennan NA et al., Influence of age and race on axial elongation in myopic children: A systematic review and meta-regression. *Optom Vis Sci* 2024;101:497-507.
3. Mark A. Bullimore et al., IMI—Interventions for Controlling Myopia Onset and Progression 2025. *Invest. Ophthalmol. Vis. Sci.* 2025;66(12):39. <https://doi.org/10.1167/iavs.66.12.39>.

Annual Eye Growth Curve

Evaluate the success of treatment in vs. physiological and myopic eye length growth



Additional information for the consultation at current age


- » Annual growth since last measurement
- » Percentage treatment efficacy¹ vs. virtual annual untreated myopia growth in Asian or Non-Asian children²
- » Ratio of emmetropic growth vs. the patient's annual growth^{1,3}

Patient data point and calculation at this age.

Appears when mouse hovers over

Unusual curve - check input
Review patient data entries and select if data should be used in the graph

Date	Old Age	Old Length	Right Eye Length	Left Eye Length	Eye	Treatment	Used to Annual Growth Calc?	Action
2019-04	12	23.5	23.5	23.5	+	EMMETROPIC	Yes	[edit] [delete]
2021-10	14	23.5	24.0	24.0	+	MYOPIA	Yes	[edit] [delete]
2022-05	15	2	24.0	24.0	+	EMMETROPIC	No	[edit] [delete]



1. Mark A. Bullimore et al., IMI—Interventions for Controlling Myopia Onset and Progression 2025. Invest. Ophthalmol. Vis. Sci. 2025;66(12):39. <https://doi.org/10.1167/iops.66.12.39>.
2. Brennan NA et al., Influence of age and race on axial elongation in myopic children: A systematic review and meta-regression. Optom Vis Sci 2024;101:497-507.
3. Yui FS. Emmetropic eye growth in East Asians and non-East Asians. Ophthalmic Physiol Opt 2023;43:1412-8.

Risk profile

Myopia risk profile imported from public questionnaire



Risk Profile

EB 2007 Date of entry: 26/05/2026 17:11 F96D-SF091C953F

The data provided suggests a low risk of developing clinically significant myopia. It is recommended to continue the questions to help refine the risk potential using other predictive factors. The data suggests a regular monitoring of vision is appropriate.

General analysis of your lifestyle

© You could Spend more time outside. There is strong evidence to suggest that spending more time outside in natural daylight will reduce the level of myopia. Reports say as little as 40 minutes a day outside can be of benefit but others believe 2 hours a day to be ideal. New research suggests Vitamin D (found in fatty fish, dairy products, red meat, liver and egg yolks) might slow down the progression of myopia.

No Risk profile available?



Go to 'My Records' and select Patient



Not available. This patient has no imported public risk profile data.

New Patient ▾ **My Records**

My Records

Show: 10 ▾ Filter: Type to filter... 🔍

Patient Code	Date Of Birth	Gender	Ethnicity	Risk profile	Actions
0001	16/01/2018	Male	White	ADD	👁️ ✎️ 🗑️

Select ADD under 'Risk profile' menu



ADD public code



Assign Booking code

Associate a public booking code to patient: 0001

Booking code

Enter Code

Close **IMPORT**

